Combination treatment shows promise against NSCLC patients ineligible for...
A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data...
View ArticleLVRC safe and effective choice for patients with severe heterogeneous emphysema
A tiny, resilient metal wire designed to gather and compress diseased lung tissue may offer relief to patients with severe heterogeneous emphysema, a subtype of the disease that involves specific,...
View ArticleSynta announces results from ganetespib Phase 2b trial on NSCLC
Synta Pharmaceuticals Corp. today announced results from an interim analysis of the Phase 2b portion of the GALAXY trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the...
View ArticleTOBI Podhaler receives FDA approval for cystic fibrosis patients with...
The U.S. Food and Drug Administration today approved TOBI Podhaler (tobramycin inhalation powder) for the management of cystic fibrosis patients with Pseudomonas aeruginosa, a bacterium that causes...
View ArticleBayer HealthCare receives FDA approval for Adempas tablets
Bayer HealthCare announced today that the United States Food and Drug Administration has approved Adempas (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic...
View ArticleInsmed reports results from ARIKAYCE phase 2 trial for treatment resistant...
Insmed Incorporated today reported results from the Company's phase 2 clinical trial of ARIKAYCETM, or liposomal amikacin for inhalation, for the treatment of patients with treatment resistant...
View ArticleSimple diagnostic algorithm to assess pulmonary embolism risk can help reduce...
Patients with suspected pulmonary embolism (PE) often undergo computed tomography pulmonary angiography (CTPA) to confirm or exclude the diagnosis.
View ArticleInsmed reports top-line data from Phase 3 study of new treatment in patients...
Insmed Incorporated, a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced top-line data from its Phase 3 CONVERT study.
View ArticleFDA grants approval for new biosimilar to treat multiple types of cancer
The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar...
View ArticleFDA approves new drug for treatment of lung disease caused by Mycobacterium...
The U.S. Food and Drug Administration today approved a new drug, Arikayce, for the treatment of lung disease caused by a group of bacteria, Mycobacterium avium complex in a limited population of...
View Article
More Pages to Explore .....